In NSCLC, mutations in BRAF are an uncommon form of genomic alteration, with a prevalence of 2% to 5% in lung adenocarcinomas.1, 2, 3 BRAF is a serine-threonine kinase of the RAS-RAF-MEK-ERK signaling cascade, a key pathway of cell proliferation, differentiation, and survival, where it activates its downstream targets MEK1 and MEK2.4 This evidence concerns the gene BRAF and non-small cell lung carcinoma.